Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PetVivo Holdings Inc (PETV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/11/2025: PETV (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7
1 Year Target Price $7
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -61.8% | Avg. Invested days 16 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 18.61M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 1 | Beta 0.85 | 52 Weeks Range 0.38 - 0.98 | Updated Date 06/30/2025 |
52 Weeks Range 0.38 - 0.98 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.44 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-06-26 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -301.45% |
Management Effectiveness
Return on Assets (TTM) -159.92% | Return on Equity (TTM) -8616.61% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 20947674 | Price to Sales(TTM) 19.46 |
Enterprise Value 20947674 | Price to Sales(TTM) 19.46 | ||
Enterprise Value to Revenue 21.91 | Enterprise Value to EBITDA -8.68 | Shares Outstanding 23559800 | Shares Floating 16029244 |
Shares Outstanding 23559800 | Shares Floating 16029244 | ||
Percent Insiders 48.51 | Percent Institutions 0.55 |
Analyst Ratings
Rating 1 | Target Price 7 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
PetVivo Holdings Inc
Company Overview
History and Background
PetVivo Holdings Inc. was founded in 2010. The company is a biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals. Significant milestones include the development and commercialization of their flagship product, SPRYNGu2122, and expansion of their product pipeline.
Core Business Areas
- Veterinary Medical Devices: Development and commercialization of medical devices for companion animals, primarily focused on osteoarthritis and joint-related conditions.
- Therapeutics: Research and development of therapeutics to treat various conditions affecting companion animals.
Leadership and Structure
John Lai serves as the Chief Executive Officer. The company's organizational structure consists of research and development, manufacturing, sales, and marketing departments.
Top Products and Market Share
Key Offerings
- SPRYNGu2122: An injectable veterinary medical device used to treat osteoarthritis in dogs, cats and horses by replacing lost cartilage. Market share data is not readily available for SPRYNG specifically, but the overall animal osteoarthritis treatment market is competitive. Key competitors include Zoetis (ZTS), Elanco Animal Health (ELAN), and Boehringer Ingelheim.
Market Dynamics
Industry Overview
The animal health industry is experiencing significant growth, driven by increasing pet ownership and rising veterinary care expenditures. The market for osteoarthritis treatments in companion animals is particularly expanding due to the aging pet population.
Positioning
PetVivo is positioned as an innovator in the animal health market with its focus on regenerative medicine for treating osteoarthritis. Their competitive advantage lies in their unique biomaterial technology.
Total Addressable Market (TAM)
The global animal health market is projected to reach hundreds of billions of US dollars. The osteoarthritis segment represents a significant portion of this market. PetVivo aims to capture a substantial share of this market with its SPRYNG product.
Upturn SWOT Analysis
Strengths
- Innovative product (SPRYNGu2122)
- Focus on regenerative medicine
- Proprietary biomaterial technology
Weaknesses
- Limited market share compared to larger competitors
- Dependence on a single core product
- Limited brand recognition
Opportunities
- Expanding pet healthcare market
- Increasing demand for regenerative therapies
- Potential for strategic partnerships
- New product development
Threats
- Competition from established animal health companies
- Regulatory hurdles
- Economic downturn impacting pet owner spending
- Adverse effects from SPRYNG treatments
Competitors and Market Share
Key Competitors
- ZTS
- ELAN
- MRK
Competitive Landscape
PetVivo faces intense competition from larger, established companies with greater resources and wider product portfolios. To compete effectively, PetVivo must focus on innovation, targeted marketing, and strategic partnerships.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is focused on development and initial commercialization. Significant growth is expected with product adoption.
Future Projections: Analyst estimates are limited. Future growth is tied to sales expansion and market penetration.
Recent Initiatives: Focus on expanding distribution channels, increasing marketing efforts, and developing new applications for their biomaterial technology.
Summary
PetVivo Holdings Inc. is a small cap biotechnology company focused on therapies for companion animals, however it faces stiff competition and is currently loss-making. Its innovative product, SPRYNGu2122, has potential, but the company needs to overcome commercialization challenges. Key considerations include successful market penetration, managing competition, and securing additional funding for growth. Its revenue growth is vital to its long term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Third-Party Financial Data Providers
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About PetVivo Holdings Inc
Exchange NASDAQ | Headquaters Edina, MN, United States | ||
IPO Launch date 2013-05-23 | CEO, President & Director Mr. John Lai | ||
Sector Healthcare | Industry Medical Devices | Full time employees 20 | Website https://www.petvivo.com |
Full time employees 20 | Website https://www.petvivo.com | ||
PetVivo Holdings, Inc., a biomedical device company, manufactures, commercializes, and licenses medical devices and therapeutics for animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. is headquartered in Edina, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.